These results suggest that ruscogenin inhibits the activation of NF-κB, leading to downregulation of proinflammatory mediators and amelioration of fibrogenesis, and therefore shows a promising effective in preventing NAFLD. Here, NFKB1 is linked to metabolic dysfunction-associated steatotic liver disease.